Guarducci, Cristina
Bonechi, Martina
Benelli, Matteo
Biagioni, Chiara
Boccalini, Giulia
Romagnoli, Dario
Verardo, Roberto
Schiff, Rachel
Osborne, C. Kent
De Angelis, Carmine
Di Leo, Angelo
Malorni, Luca
Migliaccio, Ilenia
Article History
Received: 23 May 2018
Accepted: 25 October 2018
First Online: 28 November 2018
Competing interests
: L.M. received research support from Pfizer and is a consultant/advisory board member for Pfizer, AstraZeneca, Novartis. A.D.L. is a consultant/advisory board member for Novartis, Pfizer, AstraZeneca and Lilly. R.S. received research funding from AstraZeneca, Gilead Sciences; is a consulting/advisory committee member for Macrogenics, and Eli Lilly. C.K.O. is a consultant/advisory board member for Genentech, AstraZeneca, Tolmar Pharma; received grants from Roche, Ventana, Puma; DMC Lilly; Stock: Genentech Non-financial competing interests: R.S.: Mechanisms of action of selective estrogen receptor modulators and down-regulators; Lectured at 2018 Int. Congress on the Future of Breast Cancer, Physicians’ Educational Resource, LLC; Member: AACR, ASCO, Endocrine Society; C.K.O.: Expert Witness for O’Melvery Meyers (patient case). All other authors declare no competing interest.